HAVCR1 and cardiac hypertrophy: We identified the metabolic actions of serelaxin in the heart and kidney which resulted in amelioration of ventricular hypertrophy and cardiac fibrosis, improvement of GFR, decrease of albuminuria and decreased in urinary excretion of kidney injury marker KIM-1, prevention of kidney inflammation and fibrosis, and decrease of lipid accumulation of kidney.